A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity.

@article{Moyle2012ARC,
  title={A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity.},
  author={Graeme J. Moyle and Jaime F Andrade-Villanueva and P O Girard and Andrea Antinori and Patricia Salvato and Johannes Richard Bogner and Phillip Hay and Jes{\'u}s Santos and Ludovic Astier and Miranda Pans and Agnes Balogh and Sophie Biguenet},
  journal={Antiviral therapy},
  year={2012},
  volume={17 4},
  pages={689-700}
}
BACKGROUND Abdominal adiposity in HIV-1 patients initiating antiretroviral therapy may be part of a restoration-to-health phenomenon. Lipoatrophy is associated with long-term thymidine analogue therapy. Individual protease inhibitors (PIs) differ in their effects on lipids and insulin resistance. METHODS A randomized open-label multicentre 96-week trial… CONTINUE READING